Precipio (NASDAQ:PRPO) and Pressure Biosciences (OTCMKTS:PBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.
Insider & Institutional Ownership
8.1% of Precipio shares are owned by institutional investors. 13.1% of Precipio shares are owned by insiders. Comparatively, 15.9% of Pressure Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Precipio and Pressure Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations for Precipio and Pressure Biosciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
Precipio has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Pressure Biosciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Earnings and Valuation
This table compares Precipio and Pressure Biosciences’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Precipio||$1.72 million||3.77||-$20.69 million||N/A||N/A|
|Pressure Biosciences||$2.24 million||2.75||-$10.71 million||N/A||N/A|
Pressure Biosciences has higher revenue and earnings than Precipio.
Pressure Biosciences beats Precipio on 6 of the 9 factors compared between the two stocks.
Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
About Pressure Biosciences
Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, PULSE Tubes, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions in the United States, Europe, and Asia. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.